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Introductory Chapter: 
The Multiple Etiologies of 
Preeclampsia
Nidhi Sharma
Preeclampsia is an “old” disease. “After more than a century of intensive research, 
preeclampsia and eclampsia remain an enigmatic set of conditions.”
Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet. 
2001;357:53e6.
1. Introduction
Preeclampsssia or “gestosis” or “toxemia of pregnancy” is any condition 
predisposing to eclampsia or convulsions during pregnancy. The word eclampsia 
is derived from a Greek word eklampsis meaning “lightening” or convulsions. 
Preeclampsia is speculated to be a heterogeneous group of disorders caused by mul-
tiple etiologies. Understanding the pathophysiology of this syndrome is important 
as different etiologies have different pathological mechanisms and different predic-
tive markers. Though the defect could have arisen in the renin-angiotensin system, 
cardiovascular system, liver enzyme deficiency, coagulation cascade, oxidative 
stress, or placental bed, the clinical picture is usually oversimplified as the maternal 
syndrome of hypertension, edema, and proteinuria.
The third world countries will benefit from the provision of adequate antenatal 
care after these high-risk women are identified. In the developed world, however, 
the emphasis is on early detection and prevention of preeclampsia.
During pregnancy, the physiology of cardiovascular system, renin-angiotensin 
system, pancreas changes, different organ reserves are put to test. Understanding 
preeclampsia requires the understanding of physiology of pregnancy. The blood 
flow in multiple organs is increased (Figure 1). Numerous studies at the embryo-
endometrial interphase have also suggested the association of impaired spiral artery 
remodeling in preeclampsia, but how exactly is the impaired remodeling mediated 
and what is the pathogenesis of maternal syndrome are still to be elucidated. Some 
clinical cases of maternal syndrome of preeclampsia also have normal placental 
histology, so all cases cannot be attributed to a primary placental defect.
Clinical, biochemical, and biophysical markers are used for prediction depending 
on the etiology of the maternal syndrome of preeclampsia in the pregnancy (Figure 2a 
and b). These biomarkers can specifically be used to diagnose the etiology of maternal 
syndrome as renal dysfunction (kallikrein-creatinine ratio, angiotensin sensitivity 
test), vascular resistance (uterine artery Doppler), coagulation disorders (platelet 
volume, fibronectin, prostacyclin, thromboxane), oxidative stress (lipid peroxidase, 
8-isoprostane, antioxidants, anticardiolipin antibodies, homocysteine), vascular adap-
tation (placental growth factor, vascular endothelial growth factor, s-flut, sEng), and 
placental dysfunction and ischemia (placental CRH, CRH bp, activin, inhibin, hCG).
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Atypical postpartum preeclampsia has an entirely different pathophysiology; it 
can be associated with the puerperal defects that prevent the excretion of sodium, 
puerperal diuresis. It can also be caused by an impaired shift of intravascular fluid 
into the extravascular compartment (atrial natriuretic peptide in the first week after 
delivery, natriuresis and inhibition of aldosterone, angiotensin II, vasopressin).
In this chapter the emphasis is on the preclinical pathophysiology of stage 1 of 
preeclampsia before the development of clinically evident stage 2 of hypertension, 
edema, and proteinuria.
There are two sides of fetal maternal interface, the maternal and the fetal. At the 
maternal side, the most important change is the remodeling of the spiral arterioles 
in the uterine endometrium and myometrium. The spiral arteries supply the inter-
villous space with blood in which there are floating fetal villi. Decidual veins drain 
the intervillous space.
At the fetal side, there is the development of fetal villi containing fetal capil-
laries. The fetal capillaries are covered by mesenchyme and cytotrophoblast. As 
the cytotrophoblast proliferates, it differentiates into the syncytiotrophoblast that 
covers the fetal villi. The cytotrophoblast also penetrates into the decidual stroma as 
interstitial trophoblast and also into maternal spiral arteries as endovascular tropho-
blast. The changes on both sides of fetomaternal interphase are described vide infra.
Figure 1. 
The distribution of blood flow to maternal organs during pregnancy.
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2. The maternal side of fetoplacental interface
In humans’ and primates’ placental bed, at the embryo-endometrial interface, the 
extravillous trophoblastic cells of fetal origin penetrate not only the endometrium 
but also the subendometrial or junctional zone (JZ) myometrium [1–3]. These fetal 
origin cells also penetrate the interstitium, block the spiral vessel wall, and finally 
actually get incorporated into the vessel walls resulting in wide channels ensuring 
constant slow velocity uninterrupted blood flow to the placental sinuses. The fetal 
tertiary stem villi bathe in these placental sinuses and are gently sprinkled over by 
maternal blood [4].
It was emphasized by Brosen et al. [5] that this “physiological transformation” 
of spiral arterioles at the fetomaternal interphase was a result of the phagocytotic 
action of rapidly dividing and migrating fetal trophoblast that proliferate on vascu-
lar smooth muscles and elastic membranes [6]. Some years later a maternal role in 
spiral arteriolar remodeling was discovered since a few changes in the maternal ves-
sel wall like dilatation of arterioles, immunosuppression, and rheological changes in 
the vessel wall and uterine decidua actually happen before the antidromic migration 
and proliferation of fetal trophoblast along the maternal vessel lumen [7].
The four steps of spiral arteriolar remodeling are explained below [8]. In the first 
step, there is maternal decidua-associated remodeling independent of the tropho-
blast. Encircling sheaths of edematous decidual cells around the vessels (Streeter’s 
column) appear as early as postovulatory day 11 [3]. These swollen perivascular 
cells are usually originated from vascular smooth muscles of spiral arterioles.
At 9 weeks of gestational age of the embryo, the maternal natural killer cells 
in the uterine decidua synthesize and secrete vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF), and other angiopoietins [9, 10]. This 
results in vacuolation and disorganization of endothelial cells in the vascular lumen. 
In junctional zone or subendometrial myometrium, there are no immune-modified 
natural killer cells of pregnancy, and the penetrating interstitial trophoblast helps 
the release of VEGF and angiopoietins [9, 10]. This is concluded because the inter-
stitial trophoblast enters the JZ a little later at 8 weeks.
Figure 2. 
(a) Maternal syndrome of edema, hypertension, and proteinuria, and (b) podocyte and endothelial relation 
in normal pregnancy and preeclampsia.
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After this there are actual trophoblastic proliferation and intra-arterial migra-
tion. Penetration can happen in the stroma (interstitial trophoblast) or inside 
the vessels (endovascular trophoblast). The endovascular course only takes place 
antidromically only in spiral arteries but not in veins (Figure 3).
The interstitial trophoblast subsequently fuses to form multinuclear giant cells, 
but endovascular trophoblast remains mononuclear and with phagocytosis tries to 
became a part of the vessel wall [11]. Though the multinuclear giant cells appear more 
evident on histology examination, it is the mononuclear cytotrophoblast that is more 
phagocytotic, and it proliferates widely the uterine endometrium and JZ myometrium 
within a short time (Figure 4). A large quantity of interstitial trophoblastic cells 
(basophilic mononuclear cells) proliferate in the extracellular space between the 
smooth muscles of the JZ myometrium. Trophoblast cells are distributed at the center 
at 8–14 weeks, and at 16–18 weeks, they are more migrated toward the periphery, thus 
following an enlarging ringlike pattern of centrifugal migration toward the periphery 
of the placental bed [12]. It is believed that as the trophoblastic cells fuse to form giant 
cells, they are gradually losing the ability for phagocytosis. During the transformation 
of the endometrium to decidua, there is a selective breakdown of extracellular matrix 
of stroma, and this occurs independent of fetal trophoblastic action.
The interstitial migration and proliferation of trophoblast into the decidua and 
JZ myometrium (extravascular trophoblast) precede the proliferation of trophoblast 
spiral arteries (endovascular trophoblast) by several weeks. The first thing the 
proliferating endovascular mononuclear trophoblast does is to plug the outlets of 
spiral arterioles at the fetomaternal interface and thus create a low-oxygen environ-
ment for the developing embryo. The embryo cannot tolerate a high oxygen tension. 
After 10 weeks the entire span of the spiral arteries in decidua contains trophoblast 
reaching even up to the superficial vascular JZ myometrium. Deep invasion of 
myometrial segments of the spiral arteries happens only after 15 weeks (the second 
wave of proliferation).
Figure 3. 
(A) Unmodified spiral artery showing endothelium and vascular smooth muscle, (B) Decidua associated 
remodeling with disorganization of vascular smooth muscles, (C) Interstitial Trophoblast migration enhances 
vascular smooth muscle disorganization, (D) Endovascular Trophoblast temporarily replaces to endothelium, 
(E) Intramural incorporation of endovascular trophoblast and deposition of fibrinoid, replacing the vascular 
smooth muscle, (F) Reendothelialisation and intimal thickening.
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The third step is called as trophoblast-induced remodeling when the tro-
phoblast cells actually become a part of the arterial wall. This vascular incor-
poration happens when the fetal trophoblast actually penetrates the maternal 
endothelium. Electron micrography studies of maternal decidua have revealed 
that the trophoblast penetrates between the healthy endothelial cells and 
crosses the underlying basement membrane. The smooth muscle penetration 
results in replacement of maternal endothelial cells with trophoblast embedded 
within a fibroid matrix, probably secreted by the trophoblast itself. The intra-
luminal trophoblastic cells now incorporated into the vessel wall now assume 
a spiderlike shape because of increasing accumulation of fibrinoid materials 
around the cell processes. The intraluminal trophoblast always remains mono-
nuclear or at the most becomes binuclear. This is opposite to the interstitial 
trophoblast.
The fourth step of re-endothelialization occurs when the maternal vascular 
lining is repaired by endothelial remnants, which were still present after the intra-
mural invasion. A new endothelial covering may also be derived from circulating 
endothelial progenitor cells.
Figure 4. 
(a) Placental oxygen tension curve, (b) trophoblastic penetration and placental oxygenation at 7–11 and 
12–16 weeks.
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Investigations of Jauniaux have outlined the different times in gestation at which 
the decidual spiral arteries and junctional zone spiral arteries get remodeled in 
decidual association (step 1) and endovascular trophoblast association (step 2). 
Placental oxygenation increases as gestation advances (Figure 4a and b). There 
is no connection between the spiral arteries and the intervillous space at 7 weeks. 
And they appear at 8 weeks. Even before this communication, the decidual spiral 
arteries have remodeled (Figure 5). At 7–10 weeks, there is first wave of remodel-
ing of decidual spiral arteries and early rise of intervillous flow. The second wave 
of remodeling, from 15 weeks onward, in which the endovascular trophoblast is 
observed in the junctional myometrium, is well after the steep rise in placental 
oxygenation. The decidua-associated spiral remodeling of the myometrium hap-
pens at 8–14 weeks, while trophoblastic-associated remodeling of the myometrium 
happens only after 15 weeks. The early decidua-associated remodeling of the junc-
tional myometrium essentially prepares for the rise in uteroplacental flow, while the 
subsequent trophoblast-associated remodeling only stabilizes the vessel, and the 
increased flow is maintained.
2.1 Topology of vascular remodeling
A lateral gradient of diminished invasion has been seen at the periphery of the 
placental bed as compared to the center of the placental bed. Even in normal preg-
nancies, the junctional myometrium spiral arteries are remodeled only at the center, 
and there is an absence of junctional zone myometrial vascular remodeling at the 
periphery of the placental bed. In preeclampsia the trophoblast-associated remodeling 
is restricted to the decidual spiral arteries even in the center of the placental bed. One 
Figure 5. 
(a) Syncytial apoptotic shedding in normal pregnancy, (b) trophoblastic penetration and proliferation in 
preeclampsia.
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High risk Possible explanation Prediction by Clinical features
Teenage pregnancy, short 
interval of pregnancy 
since menarche, no 
prior intercourse, and 
primipaternity
Defective infiltration of 
decidua by natural killer 
cells, ligand receptor 
interaction of leukocyte 
populations
Maternal history Maternal 
syndrome, 
proteinuria, 
hypertension, 
edema
Molar pregnancy Failed trophoblastic 
migration and intersignal. 
Ineffective blocking 
of spiral vessels and 
oxidative stress and 
embryo-endometrial 
interphase
Early first 
trimester scan
Chronic hypertension, high 
altitude pregnancy, increased 
maternal age, and diabetes
Impaired apoptosis of 
hyperplastic arterial 
smooth muscles of spiral 
arteries
Maternal 
history, insulin 
resistance, glucose 
intolerance
Connective tissue disorders, 
SLE, APLA. Factor 2 and 
factor 5 Leiden mutations, 
serpin gene mutations, and 
protein C and protein S 
deficiencies
Impaired fibrin deposition 
by trophoblasts
APLA, ANA, 
protein essay and 
genetic screening
Rh incompatibility, 
hyperhomocysteinemia
Exaggerated maternal 
healing tissue response
ABO 
incompatibility, 
Rh 
incompatibility 
screening
Vascular resistance Noncompliant maternal 
cardiovascular system
Uteroplacental 
artery flow 
waveforms, 
angiotensin II 
type 1 receptor 
agonistic 
antibodies
Oxidant stress Lipid peroxidase, 
8-isoprostane, 
antioxidants, 
hypertriglyceridemia, 
hemoglobin, iron, 
transferrin, albumin 
isoforms
Serum levels, 
plasma and tissue 
expression of the 
long pentraxin 3
Renal disease Kallikrein-creatinine Serum/urine 
levels
Coagulation, fibrinolysis 
system, platelet activation, 
markers of vascular function
Platelet volume, 
fibronectin, prostacyclin, 
thromboxane
Serum levels
Placental ischemia secondary 
to any of the above
Placental peptides, CRH, 
CRH bp, activin, inhibin, 
HCG
Ratio of 
angiogenic 
(placental 
growth factors, 
VEGF) and 
antiangiogenic 
factors (s-flut and 
s-endoglin)
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study demonstrated that even decidual segments might show incomplete remodel-
ing. It is imperative that the placental bed biopsy should be taken from an adequately 
central space and not lateral. There are less interstitial giant cells in the myometrium 
and more stacked endometrial glands pushed by the placenta at the periphery of the 
placental bed.
2.2 Failure of remodeling
2.2.1 Failure of step 1: decidua-associated remodeling is defective
Late luteal phase secretory endometrium decidualization is associated with infiltra-
tion of natural killer cells, which are now considered to be major effector cells at tropho-
blast-uterine interphase interactions. It has also been postulated that repeated cycles 
of menstrual shedding of decidualizing endometrium may act as preconditioning for 
successful implantation and deep placentation [13]. This might explain the increased 
risk of preeclampsia in teenage pregnancy, short interval of pregnancy since menarche, 
and primipaternity. This may also explain the lowered risk of preeclampsia in women 
who have intercourse earlier with partner who fathers the current pregnancy. Recent 
research also suggests that natural killer cells’ associated defects of implantation are due 
to disturbed ligand receptor interphase. Uterine natural killer cells are absent in the JZ 
myometrium, but their angiogenic action is mediated by interstitial trophoblast.
2.2.2 Failure of step 2: failed trophoblastic migration
An impaired rise in blood flow, as a result of improper decidualization and 
improper angiogenesis, leads to a failed integrin shift and a failure of trophoblast 
to acquire an endothelial phenotype. Disturbed HLA-G expression by trophoblast 
has also been postulated. This might explain preeclampsia seen in association with 
molar pregnancy.
2.2.3 Failure of step 3: trophoblast-associated remodeling is defective
Impaired intramural incorporation of endovascular trophoblast and lack of 
fibrin deposition can be caused by impaired secretion of proteinases. This may 
be because of improper trophoblast signaling. This might explain the increased 
risk preeclampsia in connective tissue disorders, SLE, and APLA. The defective 
laying down of fibrin may explain the preeclampsia in cases of thrombophilia 
disorders like factor 2 and factor 5 Leiden mutations, serpin gene mutations, 
High risk Possible explanation Prediction by Clinical features
Postpartum preeclampsia, 
inadequate mobilization of 
liquid from the interstitial 
and intravascular to 
extravascular space (6–8 L of 
the total body water, return 
of 950 mEq of total body 
sodium accumulated during 
pregnancy)
Factors affecting 
increased urinary sodium 
excretion between 3 and 
5 days after birth (increase 
of atrial natriuretic 
peptide in the first week 
after delivery, natriuresis 
and inhibition of 
aldosterone, angiotensin 
II, vasopressin)
Central venous 
pressure and 
pulmonary 
capillary wedge 
pressures, colloid 
osmotic pressure, 
pulmonary crept, 
clinical congestive 
heart failure, 
cerebral edema
Postpartum 
convulsions due to 
posterior reversible 
encephalopathy 
syndrome—
vasogenic edema 
in posterior 
brain due to lack 
of sympathetic 
modulation
Table 1. 
Possible prediction of various subtypes of preeclampsia.
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and protein C and protein S deficiencies. This might also explain the association 
of preeclampsia with placenta accreta and increta where the Nitabuch’s layer is 
absent. Chronic hypertension, renal disease, increased maternal age, and diabe-
tes may lead to hyperplasia of smooth muscles of spiral arterial media; this may 
lead to impaired maintenance of elastin and vascular smooth muscles [14, 15]. 
When these conditions are present subclinically before pregnancy, the preexist-
ing Tunica media hyperplasia might interfere with trophoblast-induced apoptosis 
of elastic smooth muscles.
2.2.4 Failure of step 4: increased maternal inflammatory response
Trophoblast proliferation and apoptosis of maternal intra-arterial smooth mus-
cles invariable incites maternal tissue repair mechanisms, it is easy to understand that 
if maternal inflammation is marked the proliferating trophoblast may be destroyed 
by lipophages resulting in “acute atherosis lesions” in the placental bed [16]. This 
might explain the occurrence of preeclampsia in Rh-incompatible pregnancies and 
hyperhomocysteinemia (Table 1).
3. The fetal side of fetoplacental interface
Syncytial sprouts arise from the syncytiotrophoblast that covers the cytotropho-
blast around the fetal stem villi. In early pregnancy large aggregates of trophoblastic 
cells proliferate and extend into the intervillous space forming drumstick-like 
syncytial structures. Syncytial sprouts are multinucleated and have large ovoid 
nuclei with very little heterochromatin. There are a large number of ribosomes with 
abundant rough endoplasmic reticulum. Larger nuclei are present in the sprouts as 
compared to other parts of syncytiotrophoblast. True sprouts are produced from 
the mesenchyme villi and immature intermediate villi (Figure 5). There are contin-
uous differentiation and proliferation of cytotrophoblast into syncytiotrophoblast 
into sprouts. This can be (a) sprout-like apoptotic shedding, (b) knots or Tenny-
Parker changes, (c) wavelike apoptotic shedding, (d) arrested apoptotic shedding, 
(e) aponecrotic shedding, and (e) necrotic shedding.
3.1 Sprout-like apoptotic shedding
This is a normal phenomenon in which villous trophoblast proliferates and differ-
entiates into cytotrophoblast. The cytotrophoblast fuses with the overlying syncytio-
trophoblast, and finally the old and aging material is packaged into apoptotic syncytial 
sprouts and released into the maternal circulation. If apoptotic shedding is blocked, the 
number of nuclei in the syncytium increases. Since it is a membrane-sealed apoptotic 
material, it does not induce an inflammatory response. In the maternal lung, the syncy-
tial sprouts get trapped and are phagocytosized by lung macrophages without inflam-
matory reaction. Approximately 3 g of apoptotically shed trophoblast is destroyed 
in the lungs daily. This is the balance of 3.6 g of cytotrophoblast that is converted to 
syncytiotrophoblast each day and 0.6 g that is retained in the syncytium [17, 18].
3.2 Tenny-Parker changes or syncytial knots
The terms syncytial sprouts and syncytial knots are different. True syncytial 
sprouts happen in first half of pregnancy when they represent early stages of large 
euchromatic nucleus. Tenny-Parker changes also called as syncytial knots are 
Prediction of Maternal and Fetal Syndrome of Preeclampsia
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bridges between the neighboring villi that look like drumstick or mushroomlike 
projections containing normally structured nuclei. These are artifacts caused by 
tangential sectioning of highly branched fetal villi.
3.3 Wavelike apoptotic shedding
In cases of placentas of fetal growth restricted with absent diastolic flow, there 
is a large decrease in the number of cytotrophoblastic cells, and the thickness of 
syncytiotrophoblast is also less [19]. The nuclei in syncytiotrophoblast accumulate 
like a ring around the vertical axis of villi. The underlying pathology is yet to be 
identified [17, 18].
3.4 Arrested apoptotic shedding
Apoptotic syncytial nuclei accumulate in knot-like structures but do not get 
extruded into the intervillous space. This is also seen in the cases of fetal growth 
restriction with absent diastolic flow. At some places the sites with nuclei are even 
larger than the cross section of villi from which they arise. It is seen that a large 
number of these giant knots form all over the placenta. In these cases the apoptotic 
cleavage of syncytial cytoskeleton may be defective [17, 18].
3.5 Aponecrotic shedding
Aponecrosis is a term used when signs of apoptotic trophoblast turnover and 
shedding are associated with signs of syncytial necrosis. Apoptosis continues with 
damaged plasma membranes, water influx and secondary hydropic changes of 
cellular structures, and release of cytoplasmic contents. This process is also called 
as secondary necrosis. Since apoptosis is a programmed cell death depending on cell 
energy, lack of cell energy reserves could be the cause of aponecrosis. These villous 
explants contain cell-free DNA, cell-free actin, and membrane-wrapped nuclei. 
In some studies in preeclampsia, the villous explants that had the packaged nuclei 
showed early signs of chromatin condensation, but the cytoplasm was edematous 
and plasma membrane had local defects.
3.6 Necrotic shedding
In pure necrotic shedding, the villous explants contain edematous nuclei in a 
hydropic cytoplasm with membrane defects. Placentas from severe preeclampsia 
and severe Rh incompatibility have shown features of necrotic shedding. The 
complete absence of chromatin condensation showed that the apoptotic pathway 
was blocked by inhibitory proteins and never restarted. In an experiment on 
pregnant guinea pigs, complete blockage of energy metabolism of trophoblast 
was done by monoiodine acetate or sodium fluoride (inhibitors of glycolysis). 
Continuous release of necrotic villous explants leads to the features of pre-
eclampsia [17, 18].
If cytotrophoblast keeps growing and accumulating as syncytiotrophoblast and 
does not shed, it will lead to intrasyncytial accumulation of old and aged tropho-
blastic components which finally necrose. Cytoplasmic blebbing of syncytium with 
nuclear and cytoplasmic edema is a hallmark feature of necrotic shedding. Though 
there are phenotypic similarities among different types of villous explants, there are 
differences in modes of nuclear chromatin aggregation, nuclear or cytosolic edema. 
Cracks in the plasma membrane help to differentiate between physiological apop-
totic shedding and pathological necrotic shedding.
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4. Placenta as a casualty and not the cause
4.1 Liver pathology as a cause of preeclampsia
Preeclampsia is associated with three unique liver lesions described as liver 
lesions of preeclampsia, HELLP syndrome, and acute fatty liver of pregnancy. 
HELLP syndrome has classical periportal or focal parenchymal liver necrosis. There 
is thrombotic microangiopathy with resulting hemolysis and liver damage. Few 
cases of HELLP are associated with defects in beta-oxidation of fatty acids. There 
is microangiopathic hemolytic anemia with schistocytes, thrombocytopenia, and 
elevated levels of ALT/AST/LDH/bilirubin. HELLP may even develop postpartum, 
so the placenta is an unlikely cause of HELLP syndrome (Figure 6).
Acute fatty liver of pregnancy is due to defective oxidation of beta fatty acids. 
There is mitochondrial deficiency of long-chain 3-hydroxyacyl coenzyme A dehy-
drogenase in fetus. This leads to accumulation of 3-hydroxyacyl metabolites that are 
toxic to the liver. Half of the pregnancies with acute fatty liver of pregnancy develop 
preeclampsia (Figure 7).
4.2 Renin-angiotensin system as a cause of preeclampsia
The renin-angiotensin system (RAS) recognizes pregnancy very early. In 
the luteal phase of menstrual cycle, the RAS is activated under the influence of 
progesterone, and if pregnancy occurs, this RAS activation is maintained. This 
activation of RAS may be caused by progesterone that is natriuretic or it could be 
the “perceived under filling” of circulation by macula densa in early pregnancy. 
Juxtaglomerular apparatus synthesizes and releases renin, an aspartyl protease. 
Estrogen simultaneously binds to the promoter region of alpha-2 globulin angio-
tensinogen (AOGEN) and leads to the synthesis of angiotensinogen. Plasma 
Figure 6. 
Pathogenesis of preeclampsia in LACHD deficient fetus.
Prediction of Maternal and Fetal Syndrome of Preeclampsia
12
angiotensin II (AGII) rises and leads to the synthesis and release of aldosterone 
from the zona glomerulosa in the adrenal cortex. The pregnant women do not 
develop hypertension from the presser effects of AGII due to the downregulation 
of ATR1 receptors. The vessel responsive to adrenal cortisol is usually unaltered in 
pregnancy [20, 21].
Angiotensin II is very peculiar because its action depends on which of its two 
receptors it is acting. When AGII binds with AGI receptors, it causes vasoconstric-
tion, but when it binds to AGII receptors, it causes vasodilation. If angiotensin I 
receptors are downregulated during pregnancy or by angiotensin receptor blockers 
like telmisartan or if angiotensin II receptors are upregulated during fetal life, it is a 
vasodilator.
Villous syncytiotrophoblast has high density of angiotensinase A (aminopep-
tidase A) which converts angiotensin II to angiotensin III [22, 23]. The increase 
in this angiotensinase activity is also responsible for downregulation of ATR1 
receptors in normal pregnancy [24]. It was observed that during cesarean section 
in normal pregnancy, the uterine venous AGII is lower than the peripheral venous 
AGII. In preeclampsia pregnancy, uterine venous AGII are higher than peripheral 
AGII level [25].
In prospective studies it has been demonstrated that aminopeptidase A levels 
were high before the clinical syndrome of preeclampsia but levels were lower after 
preeclampsia clinically developed [24]. The initial rise in trophoblastic aminopepti-
dase could be an initial homeostatic response protecting placenta from the harmful 
effects of locally generated AGII.
The receptor for angiotensin IV is also called as insulin-regulated aminopepti-
dase (IRAP). High concentrations of IRAP are present on human placenta [26]. In 
the second half of pregnancy, the extracellular domain of this receptor is shed off. 
Angiotensin IV acts as an endogenous inhibitor of angiotensin-converting enzyme. 
It stimulates both RNA and DNA synthesis in endothelial cells and proliferation of 
endothelial cells. It can also increase the levels of plasminogen activator inhibitor 
Figure 7. 
Pathogenesis of preeclampsia in a nonresilient cardiovascular system. The autonomic nervous system, intrinsic 
smooth muscle reflexes, and the endothelium influence vascular tone.
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mRNA. It is a vasodilator at least in cerebral vessels. These features are important 
because angiotensin IV can be involved in local apoptosis and remodeling.
4.3 Noncompliant cardiovascular system as a cause of preeclampsia
In preeclampsia there may be an impaired vasodilator response to endothelium-
dependent agonists such as acetylcholine and bradykinin (Figure 7). Various adap-
tive mechanisms are employed at the fetomaternal interphase, and subsequently 
after 20 weeks, a clinically evident maternal syndrome of hypertension, edema, and 
proteinuria develops. The development of second stage of late vascular dysfunction 
can also happen independent of first stage. The uterine artery Doppler waveform 
becomes transformed into a high flow with low resistance at 22–24 weeks in normal 
gestation. However, in preeclampsia there is a latent preclinical stage with impaired 
intravascular volume expansion, hyperdynamic circulation, and a decreased cardiac 
output as clinical disease develops. This decreased cardiac output leads to renal and 
uteroplacental insufficiency. There may also be leaky capillaries leading to pulmo-
nary and cerebral edema. Severe and early-onset preeclampsia has abnormal uterine 
artery waveform in preclinical stage and hypertension in clinical stage. Abnormal 
Doppler of uterine artery may be considered as a local noninvasive imaging of a 
more generalized systemic vasculopathy. This may mediate further cardiovascular 
risks. Women with preeclampsia are also two and a half times likely to die from 
ischemic heart disease in later life [27–29]. Several studies have been conducted 
showing preeclampsia association with the high pulsatility index of uterine artery.
Raised uterine artery impedance is a marker of early endothelial dysfunction. 
It is associated with increased aortic pulse wave velocity and augmentation index 
in the first trimester of pregnancy that is the marker of future cardiovascular risk 
[30–32]. Increased homocysteine levels have also been implicated in both cardiovas-
cular risks and preeclampsia [33].
5. Conclusion
Preeclampsia is a heterogeneous disease. The late-onset preeclampsia at or 
near term has low fetal and maternal morbidity. But the early-onset preeclampsia 
(1%) of all preeclampsia has significant risks. Prediction of risks and identifi-
cation of subclinical disease are mandatory. The majority of at-risk groups in 
multigravida are chronic hypertension, pregestational and gestational diabetes, 
age, and multiple fetuses, whereas in primigravida only 14% have these risks. If 
there is preeclampsia in a multigravida, a nonplacental cause should be definitely 
considered. This suggests that there are multiple underlying etiologies of different 
clinical presentations. Table 1 summarizes the likely etiopathogenesis in different 
clinical scenarios. Postpartum eclampsia can be predicted and monitored with 
central venous pressure and pulmonary capillary wedge pressure [34–36]. The 
maternal syndrome (proteinuria, edema, and hypertension) also has differences 
in time of onset, severity, and organ system involvement as highlighted in several 
studies [37–39]. There is a rising interest in galectin molecules for prediction of 
these subtypes (Figure 8). These clinical subpopulations need to be identified 
and preeclampsia predicted with rigorous definition of different biomarkers of 
different clinical phenotypes [40–44]. The future endeavors should be to identify 
subclinical disease in various clinical phenotypes with these potential biomarkers 
in prospective longitudinal studies.
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Figure 8. 
Galectin subtypes and prediction of preeclampsia.
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